Tyrosine kinase inhibitor
This page covers all Tyrosine kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting BCR-ABL, KIT, PDGFRA, Tyrosine kinases, vascular endothelial growth factor receptors (VEGFRs).
Targets
BCR-ABL, KIT, PDGFRA · Tyrosine kinases · vascular endothelial growth factor receptors (VEGFRs) · VEGFR, FGFR, and related receptor tyrosine kinases · VEGFR · VEGFR2 · Tyrosine kinases (e.g. EGFR, HER2, BCR-ABL) · Multiple receptor tyrosine kinases (RTKs) · HER2/neu · KIT, PDGFRA
Marketed (3)
- imatinib (IM) · First Affiliated Hospital, Sun Yat-Sen University · Oncology
Imatinib is a tyrosine kinase inhibitor that blocks the BCR-ABL fusion protein and other kinases, preventing abnormal cell proliferation in chronic myeloid leukemia and gastrointestinal stromal tumors. - Sitravatinib · Pfizer · Oncology
- Axitinib (AG-013736) · Pfizer · Oncology
Phase 3 pipeline (29)
- HRS-4642 + AG · Jiangsu HengRui Medicine Co., Ltd. · Oncology
HRS-4642 is an anti-angiogenic tyrosine kinase inhibitor that blocks multiple receptor tyrosine kinases involved in tumor vascularization and growth. - Vorolanib Tablets+Everolimus · Peking University Cancer Hospital & Institute · Oncology
Vorolanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), and Everolimus is an mTOR inhibitor. - Rivoceranib (Apatinib) · Jiangsu HengRui Medicine Co., Ltd. · Oncology
Rivoceranib (Apatinib) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2). - TKI · Shenzhen TargetRx Co., Ltd. · Oncology
TKI inhibits tyrosine kinases to block cancer cell proliferation and survival. - OTX-TKI · Ocular Therapeutix, Inc. · Ophthalmology
OTX-TKI is a tyrosine kinase inhibitor designed for topical ocular delivery to treat eye surface diseases. - Pyrotinib in combination with Capecitabine. · Jiangsu HengRui Medicine Co., Ltd. · Oncology
Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, and when combined with Capecitabine, it is used to treat HER2-positive breast cancer. - DCC-2618 · Deciphera Pharmaceuticals, LLC · Oncology
DCC-2618 is a tyrosine kinase inhibitor that targets KIT, PDGFRA, and other receptor tyrosine kinases involved in gastrointestinal stromal tumors and other malignancies. - Imatinib (Glivec) · Dermatologic Cooperative Oncology Group · Oncology
Imatinib is a tyrosine kinase inhibitor that blocks the BCR-ABL fusion protein and other kinases, preventing abnormal cell proliferation in chronic myeloid leukemia and gastrointestinal stromal tumors. - OTX-TKI (axitinib implant) · Ocular Therapeutix, Inc. · Oncology
OTX-TKI (axitinib implant) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors. - Supportive care+Ripertamab · Air Force Military Medical University, China · Oncology
Ripretinib targets and inhibits the activity of KIT and PDGFRA kinases, which are involved in the growth and spread of cancer cells. - HR-1703 · Guangdong Hengrui Pharmaceutical Co., Ltd · Oncology
HR-1703 is a tyrosine kinase inhibitor that targets specific oncogenic pathways to inhibit tumor cell growth and proliferation. - targeted drug · Nanfang Hospital, Southern Medical University · Oncology
This targeted drug works by binding to a specific protein on cancer cells, preventing them from growing and dividing. - Imatinib maintenance · Centre Leon Berard · Oncology
Imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases to prevent cancer cell proliferation. - Imatinib mesylate (STI571) · M.D. Anderson Cancer Center · Oncology
Imatinib is a tyrosine kinase inhibitor that blocks the BCR-ABL fusion protein and other kinases, preventing abnormal cell proliferation in chronic myeloid leukemia and other cancers. - surufatinib + gemcitabine + nab-paclitaxel · Tianjin Medical University Cancer Institute and Hospital · Oncology
Surufatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR). - interruption of Glivec® · Centre Leon Berard · Oncology
Glivec is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. - ICP-332 Tablets · Beijing InnoCare Pharma Tech Co., Ltd. · Oncology
ICP-332 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells. - Imatinib Mesylate and Nilotinib · University Hospital, Lille · Oncology
Imatinib and nilotinib are tyrosine kinase inhibitors that block BCR-ABL and other oncogenic kinases to suppress abnormal cell proliferation in chronic myeloid leukemia. - Sequential Lenvatinib · Sun Yat-sen University · Oncology
Sequential lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR). - HRS-8427 · Jiangsu HengRui Medicine Co., Ltd. · Oncology
HRS-8427 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells. - TQ-B3139 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Oncology
TQ-B3139 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and survival. - Tyrosine kinase inhibitor · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Oncology
Tyrosine kinase inhibitors block the activity of specific enzymes called tyrosine kinases, which are involved in the activation of proteins by signal transduction cascades. - treatment of TKI in CML · Poitiers University Hospital · Oncology
This drug targets the BCR-ABL protein to inhibit cancer cell growth in chronic myeloid leukemia. - Pazopanib Oral Tablet [Votrient] · Centre Leon Berard · Oncology
Pazopanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and c-KIT. - Masitinib (4.5) · AB Science · Oncology, Immunology, Neurology
Masitinib is a tyrosine kinase inhibitor that selectively targets c-KIT, PDGFR, and Lyn kinases to modulate immune cell function and reduce pathological inflammation. - Masitinib (6.0) · AB Science · Neurology, Immunology, Oncology
Masitinib is a tyrosine kinase inhibitor that selectively targets c-Kit, PDGF receptor, and Lyn kinase to modulate immune cell activation and reduce inflammatory responses. - HRS-9231 · Jiangsu HengRui Medicine Co., Ltd. · Oncology
HRS-9231 is a tyrosine kinase inhibitor that targets multiple kinases involved in cancer cell proliferation and angiogenesis. - TQB2450+Anlotinib · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Oncology
TQB2450 is a tyrosine kinase inhibitor, and Anlotinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor. - Vandetanib (SAR390530) · Genzyme, a Sanofi Company · Oncology
Vandetanib is a tyrosine kinase inhibitor that targets RET, VEGFR2, and EGFR.
Phase 2 pipeline (13)
- Flonoltinib Maleate · Chengdu Zenitar Biomedical Technology Co., Ltd · Oncology
Flonoltinib maleate is a tyrosine kinase inhibitor that targets the BCR-ABL1 protein. - Bezuclastinib in combination with sunitinib · Sarcoma Alliance for Research through Collaboration · Oncology
Bezuclastinib is a tyrosine kinase inhibitor that targets KIT and PDGFRα, and in combination with sunitinib, it is used to treat gastrointestinal stromal tumors (GIST). - AK104 lenvatinib · Akeso · Oncology
AK104 lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR). - ANG-3070 · Angion Biomedica Corp · Cardiovascular
ANG-3070 is a tyrosine kinase inhibitor that targets angiopoietin signaling to promote vascular stabilization and tissue repair. - EKB-569 · Wyeth is now a wholly owned subsidiary of Pfizer · Oncology
EKB-569 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. - AT13387 and Imatinib · Astex Pharmaceuticals, Inc. · Oncology
AT13387 is a potent and selective inhibitor of the B-Raf V600E kinase, while Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-Kit, and PDGFR. - Imatinib tablets · Centre Leon Berard · Oncology
Tyrosine kinase inhibitor - Gleevec and Arsenic Trioxide · New Mexico Cancer Research Alliance · Oncology
Tyrosine kinase inhibitor - AC220 · Therapeutic Advances in Childhood Leukemia Consortium · Oncology
Tyrosine kinase inhibitor - ApatinibMesylateTablets · Chang-Ming Huang, Prof. · Oncology
Tyrosine kinase inhibitor - Icotinib Hydrochloride Tablets · Betta Pharmaceuticals Co., Ltd. · Oncology
Tyrosine kinase inhibitor - Gefitinib, raltitrexed · AstraZeneca · Oncology
Tyrosine kinase inhibitor - Apatinib Combined With Docetaxel · Jiangsu ShengDiYa Medicine Co., Ltd. · Oncology
Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.
Phase 1 pipeline (3)
- AK104 IV infusion；Chiauranib oral · Akeso · Oncology
Tyrosine kinase inhibitor - Apatinib Mesylate, Gefitinib · Jiangsu HengRui Medicine Co., Ltd. · Oncology
Tyrosine kinase inhibitor of VEGFR-2 and c-KIT - Axitinib Tablets · Nanjing Leads Biolabs Co.,Ltd · Oncology
Axitinib is a selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3).